BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.55
-0.39 (-3.92%)
At close: Jun 29, 2026, 4:00 PM EDT
9.68
+0.13 (1.35%)
Pre-market: Jun 30, 2026, 8:21 AM EDT
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $156.41M in the quarter ending March 31, 2026, with 7.48% growth. This brings the company's revenue in the last twelve months to $322.75M, up 42.55% year-over-year. In the year 2025, BioCryst Pharmaceuticals had annual revenue of $874.84M with 94.10% growth.
Revenue (ttm)
$322.75M
Revenue Growth
+42.55%
P/S Ratio
2.74
Revenue / Employee
$2,036,129
Employees
435
Market Cap
2.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.84M | 424.13M | 94.10% |
| Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
| Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
| Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
| Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
| Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
| Dec 31, 2019 | 48.84M | 28.18M | 136.45% |
| Dec 31, 2018 | 20.65M | -4.53M | -18.00% |
| Dec 31, 2017 | 25.19M | -1.17M | -4.43% |
| Dec 31, 2016 | 26.35M | -21.90M | -45.39% |
| Dec 31, 2015 | 48.26M | 34.65M | 254.62% |
| Dec 31, 2014 | 13.61M | -3.72M | -21.48% |
| Dec 31, 2013 | 17.33M | -8.96M | -34.09% |
| Dec 31, 2012 | 26.29M | 6.65M | 33.85% |
| Dec 31, 2011 | 19.64M | -42.74M | -68.51% |
| Dec 31, 2010 | 62.38M | -12.21M | -16.37% |
| Dec 31, 2009 | 74.59M | 18.03M | 31.87% |
| Dec 31, 2008 | 56.56M | -14.68M | -20.60% |
| Dec 31, 2007 | 71.24M | 65.03M | 1,046.79% |
| Dec 31, 2006 | 6.21M | 6.06M | 3,990.38% |
| Dec 31, 2005 | 151.87K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.53B |
| Perrigo Company | 4.18B |
| Trulieve Cannabis | 1.17B |
| Prestige Consumer Healthcare | 1.09B |
| ANI Pharmaceuticals | 923.71M |
| Supernus Pharmaceuticals | 776.83M |
| HUTCHMED (China) | 548.51M |
| Xeris Biopharma Holdings | 314.85M |
BCRX News
- 1 hour ago - BioCryst price target raised to $29 from $27 at Cantor Fitzgerald - TheFly
- 1 day ago - BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs - Reuters
- 1 day ago - BioCryst to discontinue internal discovery programs, close Alabama facility - TheFly
- 1 day ago - BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility - GlobeNewsWire
- 18 days ago - BioCryst to present new Orladeyo data at EAACI - TheFly
- 18 days ago - BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire
- 20 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts